ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%
Market cap
$3.4B
P/E
8.5×
Fwd P/E
55.6×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
11.24 9.98 11.51 13.68

+8 more quarters

P/S ratio
3.81 3.47 4.20 3.44
P/FCF ratio
0.00 0.00 0.00 56,296.25
P/Operating CF
43.08 111.70 (92.28) 48.50
P/B ratio
3.32 3.04 3.66 3.93
EV/Sales
2.97 2.69 3.43 2.63
EV/EBITDA
35.22 33.10 33.08 11.14
EV/FCF
(65.04) (35.02) (39.55) 43,064.04
Current Ratio
3.39 3.59 3.83 3.02
Net Debt/EBITDA
(23.36) 410.14 (41.72) (22.52)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
8.89% 10.02% 8.69% 7.31%
Free Cash Flow Yield
(1.20%) (2.22%) (2.07%) 0.00%
Free Cash Flow per Share
0.56 0.17 (0.31) (0.15)
Book value per Share
7.61 7.32 7.29 5.43
Free Cash Flow
95.69 28.77 (52.74) (24.94)
EV/EBIT
39.20 36.39 35.08 11.44
Other line items

Show all line items

Columns are period end dates